Preoperative Leuprolide Acetate in a perimenopausal patient carrying large leiomyomas

Article Sidebar

PDF (Español (España))
Published: Mar 11, 2022
DOI: https://doi.org/10.21676/2389783X.4490
Keywords:
Leiomyoma, Myoma, Leuprolide, Perimenopause
Preoperative Leuprolide Acetate in a perimenopausal patient carrying large leiomyomas

Main Article Content

Javier Augusto Sánchez Flórez
Hospital Universitario Julio Méndez Barreneche
https://orcid.org/0000-0002-7466-7583
Carla Lorena Macchia-de Sánchez
Universidad del Magdalena
https://orcid.org/0000-0003-2822-2943

Abstract

Uterine leiomyomas are common during reproductive years. In symptomatic patients with multiple and large elements, surgical treatment is preferred. There are less frequent cases in which the huge size of the uterus warrants preoperative medical treatment. The goal is to reduce its size and vascularity. Taking this into account, the role of selective progesterone receptor modulators, such as ulipristal, and gonadotropin-releasing hormone agonists, such as leuprolide acetate, has been highlighted. The first one, with a pharmacovigilance alert at 2018 for severe liver injury. The second, with selective use due to the side effects of hypoestrogenemia. We present a case of a patient with large fibroids in whom pre-surgical treatment with leuprolide acetate was carried out, with an optimal response. Based on the case presented, it is intended to promote reflection and the integration of current concepts in pre-surgical therapeutic options aimed at patients with large fibroids. The judicious therapeutic choice will be aimed at improving the quality of life in a framework of safety for the patient.

Downloads

Download data is not yet available.

Article Details

How to Cite
Sánchez Flórez , J. A., & Macchia-de Sánchez, C. L. (2022). Preoperative Leuprolide Acetate in a perimenopausal patient carrying large leiomyomas. Duazary, 19(1), 64–71. https://doi.org/10.21676/2389783X.4490
Issue
Vol. 19 No. 1 (2022): (January - March)
Section
Clinical report
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Commercial use of the original work or of possible derivative works is not allowed, the distribution of which must be done with a license equal to that which regulates the original work.
 
 
 
 

References

Borahay MA, Asoglu MR, Mas A, Adam S, Kilic GS, Al-Hendy A. Estrogen Receptors and Signaling in Fibroids: Role in Pathobiology and Therapeutic Implications. Reprod Sci. 2017;24(9):1235-1244. Doi: https://dx.doi.org/10.1177/1933719116678686

Donnez J, Dolmans MM. Uterine fibroid management: From the present to the future. Hum Reprod Update. 2016;22(6):665-686. Doi: https://dx.doi.org/10.1093/humupd/dmw023

Yu X, Fu J, Cao T, Huang L, Qie M, Ouyang Y. Clinicopathologic features and clinical outcomes of intravenous leiomyomatosis of the uterus: A case series. Medicine. 2021;100(1): e24228. Doi: https://dx.doi.org/10.1097/MD.0000000000024228

Schetz M, De Jong A, Deane AM, Druml W, Hemelaar P, Pelosi P, et al. Obesity in the critically ill: a narrative review. Intensive Care Med. 2019;45(6):757-769. Doi: https://dx.doi.org/10.1007/s00134-019-05594-1

Laughlin SK, Stewart EA. Uterine leiomyomas: Individualizing the approach to a heterogeneous condition. Obstet and Gynec. 2011; 117(2): 396–403. https://dx.doi.org/10.1097/AOG.0b013e31820780e3

Vilos GA, Allaire C, Laberge PY, Leyland N, Vilos AG, Murji A, et al. The Management of Uterine Leiomyomas. J Obstet Gynaecol Canada. 2015;37(2):157–78. Doi: https://dx.doi.org/10.1016/S1701-2163(15)30338-8

Laughlin-Tommaso SK, Lu D, Thomas L, Diamond MP, Wallace K, Wegienka G, et al. Short-term quality of life after myomectomy for uterine fibroids from the COMPARE-UF Fibroid Registry. Am J Obstet Gynecol. 2020; 222:345.e1–22. Doi: https://dx.doi.org/10.1016/j.ajog.2019.09.052

Munro MG, Critchley HO, Broder MS, Fraser IS; FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynecol Obstet. 2011;113(1):3–13. Doi: https://dx.doi.org/10.1016/j.ijgo.2010.11.011

Al-Hendy A, Salama SA. Ethnic distribution of estrogen receptor-α polymorphism is associated with a higher prevalence of uterine leiomyomas in black Americans. Fertil Steril. 2006;86(3):686-693. Doi: https://dx.doi.org/10.1016/j.fertnstert.2006.01.052

Malik M, Britten J, Cox J, Patel A, Catherino WH. Gonadotropin-releasing hormone analogues inhibit leiomyoma extracellular matrix despite presence of gonadal hormones. Fertil Steril. 2016;105(1):214-224. Doi: https://dx.doi.org/10.1016/j.fertnstert.2015.09.006

European Medicines Agencies. Ulipristal acetate for uterine fibroids: EMA recommends restricting use. Published 2021. Accessed May 7, 2021. Available at: https://www.ema.europa.eu/en/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids_en.pdf

Chang WC, Chu LH, Huang PS, Huang SC, Sheu BC. Comparison of Laparoscopic Myomectomy in Large Myomas With and Without Leuprolide Acetate. J Minim Invasive Gynecol. 2015;22(6):992-996. Doi: https://dx.doi.org/10.1016/j.jmig.2015.04.026

Di Lieto A, De Falco M, Pollio F, Mansueto G, Salvatore G, Somma P, et al. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas. J Soc Gynecol Investig. 2005;12(2):123-128. Doi: https://dx.doi.org/10.1016/j.jsgi.2004.10.008

American College of Obstetricians and Gynecologists (ACOG). Management of Symptomatic Uterine Leiomyomas. Practice Bulletin Summary, Number 228. Obstet Gynecol [Internet]. 2021;137(6):1131–3. Doi: https://dx.doi.org/10.1097/AOG.0000000000004403

Lethaby A, Puscasiu L, Vollenhoven B. Preoperative medical therapy before surgery for uterine fibroids. Cochrane Database Syst Rev. 2017;2017(11):CD000547. Doi: https://dx.doi.org/10.1002/14651858.CD000547.pub2

Most read articles by the same author(s)